Rate Video

ASH 2019 | Relapsed myeloma reports: CAR-T, bispecific Abs & combinations

Mohamad Mohty • 7 Dec 2019

Multiple Myeloma Antibodies CAR-T Carfilzomib Daratumumab Dexamethasone

CANDOR CARTITUDE-1

Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, shares his overview of the latest updates for multiple myeloma (MM) in the relapsed setting from the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL. Prof. Mohty specifically discusses CAR-T, bispecific antibodies and new combination regimens.

Defibrotide in VOD/SOS after HSCT

Induction in myeloma: a journey over time

ATG and/or post-Cy for GvHD prophylaxis

Mohamad Mohty • 31 Aug 2020

Does maintenance therapy increase overall survival in myeloma?

Andrew Spencer et al. • 13 Sep 2019

Related Videos

Addition of daratumumab to R/R myeloma regimens improves outcomes

Saad Usmani • 18 Dec 2020

Bispecific antibodies for myeloma: highlights from ASH 2020

Saad Usmani • 17 Dec 2020

Ide-cel CAR T-cell therapy in newly diagnosed high-risk myeloma

Saad Usmani • 17 Dec 2020

Anti-BCMA CAR T-cell therapy in myeloma: updates from ASH 2020

Saad Usmani • 17 Dec 2020